Developer docs
API playgroundTry for free, no card

Search company profiles

GenEditBio

Full company profile

uuid0002334

Namestring
GenEditBio
Legal namestring
GenEditBio Limited
Websiteurl
geneditbio.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

GenEditBio (GenEditBio Limited) is a clinical-stage biotechnology company founded in 2021 and headquartered in Hong Kong, with research operations in Beijing and a supporting office in Boston. The company develops CRISPR-based in vivo genome-editing therapies — framed as "DNA surgery" — for genetic diseases with unmet medical needs, with primary focus on ocular, metabolic, rare, and cardiovascular indications. Its lead program GEB-101 is a first-in-class, single intrastromal injection CRISPR-Cas therapy for TGFBI corneal dystrophy; it received FDA IND clearance in January 2026 and NMPA clinical trial approval in July 2026, with a Phase 1/2 CLARITY trial underway in the United States. A second program, GEB-200, targets cardiovascular disease and is being advanced through a cross-license with ToolGen.

The company's underlying technology platform integrates three pillars: (1) GenomePAM, an AI-integrated system for PAM characterization and engineering of CRISPR-Cas nucleases using mammalian genome repeats and AlphaFold 3, published in Nature Biomedical Engineering; (2) Protein Delivery Vehicles (PDV), replication-incompetent viral-like particles for in vivo RNP delivery with programmable tissue targeting; and (3) Lipid Nanoparticle (LNP) delivery technology with proprietary NHP-barcoded high-throughput screening. Novel high-fidelity Cas nucleases (SpCas9-HF, SaCas9-HF) and off-target monitoring methods (GUIDE-Seq, EDITED-Seq) underpin the editing precision layer.

GenEditBio is pre-commercial and does not yet generate product revenue. Its forward revenue mechanics are structured around two streams: future therapeutic development and commercialization of its pipeline (potentially via licensing or direct sales through clinical trial sites and ultimately healthcare providers), and technology licensing and partnerships generating upfronts, milestones, and royalties — exemplified by the ToolGen cross-license and the Yimingbio/Ubrigene LNP ex vivo licensing deal. The company sells through enterprise field sales motions targeting pharmaceutical partners, CROs, and global investigators, and reaches investors and partners through international biotech conferences such as the BioCentury-BayHelix East-West Summit and Web Summit Qatar. Backed by $90 million in disclosed financing (April 2024) led by Center Ventures and Shuntian Pharmaceuticals, plus Qiming Venture Partners, HKSTP, and others, and recognized on the Forbes Asia 100 To Watch 2025 list, GenEditBio operates with 51–100 employees across Hong Kong, Beijing, and Boston.

Short descriptiontext

GenEditBio is a clinical-stage Hong Kong-headquartered biotechnology company developing CRISPR-based in vivo genome-editing therapies for ocular, cardiovascular, and rare genetic diseases, leveraging proprietary LNP and PDV delivery platforms and the AI-integrated GenomePAM nuclease discovery platform.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersHong Kong, Hong Kong SAR China
HQ citystring
Hong Kong
HQ countrystring
Hong Kong SAR China
HQ regionstring
Asia
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
gene editing therapy, CRISPR therapeutics, lipid nanoparticle delivery, protein delivery vehicle, genomic medicine
Industry5 codes
PRIMARYHLAAACAD
Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAI
Cardiometabolic & Other Systemic Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAL
Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAAIAG
CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Gene Therapy
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Therapeutic Development and Commercialization
TypeOne Time License
Description

GenEditBio is a clinical-stage biotechnology company developing CRISPR-based genome editing therapies. The company generates revenue through the development and potential commercialization of its therapeutic pipeline, including GEB-101 for TGFBI corneal dystrophy and GEB-200 for cardiovascular disease.

geneditbio.com
2Technology Licensing and Partnerships
TypeLicensing Royalties
Description

The company engages in strategic licensing agreements and partnerships, such as the cross-license agreement with ToolGen, to develop and commercialize genome-editing therapeutics, generating revenue through upfront payments, milestone payments, and royalties.

prnewswire.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

GenEditBio is a clinical-stage biotechnology company developing CRISPR-Cas based in vivo genome editing therapies for genetic diseases. Its integrated platform combines proprietary lipid nanoparticle (LNP) and protein delivery vehicle (PDV) delivery technologies, novel Cas nucleases, and the GenomePAM AI platform for nuclease discovery. The lead clinical asset GEB-101 is a first-in-class CRISPR therapy for TGFBI corneal dystrophy, with GEB-200 in development for cardiovascular disease.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • FDA IND clearance achieved for GEB-101, marking transition from preclinical to clinical stage
+2 more records
Product overview1 text field

GenEditBio is a clinical-stage biotechnology company developing CRISPR-based precision genome editing medicines. The company's integrated platform combines three core technologies: LNP (Lipid Nanoparticle) delivery technology for organ/tissue targeting, PDV (Protein Delivery Vehicle) for viral-like in vivo RNP delivery, and GenomePAM for AI-powered CRISPR-Cas nuclease discovery and engineering. The lead clinical program GEB-101 is a first-in-class CRISPR therapy for TGFBI corneal dystrophy, with GEB-200 in development for cardiovascular disease. The company focuses on 'one-and-done' in vivo gene editing therapies targeting ocular, metabolic, and rare diseases.

Product and service5 records
1GEB-101
CategoryCore therapeutic product
Description

First-in-class CRISPR-Cas based in vivo genome editing therapy for TGFBI corneal dystrophy, delivered via single intrastromal injection using ribonucleoprotein (RNP) formulation. Targeting patients with TGFBI corneal dystrophy.

2GEB-200
CategoryCore therapeutic product
Description

In vivo genome editing therapeutic candidate for cardiovascular disease, developed in collaboration with ToolGen using CRISPR-Cas9 platform and GenEditBio's lipid nanoparticle delivery technology. Targets cardiovascular genetic conditions with unmet needs.

3GenomePAM Platform
CategoryPlatform / technology
Description

AI-integrated scalable platform for protospacer adjacent motif (PAM) characterization and engineering of CRISPR-Cas nucleases using mammalian genome repeats. Achieves at least 10-bit width PAM analysis compared to traditional 5-6 bit width methods, accelerating novel Cas nuclease discovery.

4Protein Delivery Vehicle (PDV)
CategoryDelivery technology platform
Description

Proprietary replication-incompetent viral-like particle for in vivo delivery of genome editors as RNP, featuring programmable tissue targeting via surface glycoproteins and molecules, high cargo compatibility and large cargo capacity.

5Lipid Nanoparticle (LNP) Delivery Technology
CategoryDelivery technology platform
Description

Proprietary lipid nanoparticle delivery platform featuring barcoding technology that enables high-throughput screening directly on nonhuman primates, with diverse lipid components enabling organ/tissue targeting without requiring antibody conjugation.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-26
Description

Strategic collaboration to develop next-generation LNP ex vivo delivery technology. Yimingbio licensed GenEditBio's LNP technology for ex vivo applications and will leverage its global CRDMO production services for engineering integration and product development. Focus on developing efficient, low-toxicity RNA-LNP ex vivo delivery standardized ready-to-use reagent products for cell and gene therapy.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-11-24
Description

Strategic cross-license agreement for the development of in vivo genome-editing therapeutics. Collaboration leverages ToolGen's CRISPR-Cas9 platform and GenEditBio's lipid nanoparticle delivery technology. Focuses on 'once-and-done' treatment for diseases with unmet needs, with promising preclinical results on GEB-200 for cardiovascular disease.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Pioneering CRISPR/Cas9-based gene editing company with approved therapy (Casgevy) and broad pipeline. Direct peer with overlapping gene editing platform and delivery technology approaches for in vivo applications.

TypeDirect peer
Description

Clinical-stage precision genetic medicines company developing base editing therapies for serious diseases. Comparable gene editing platform with similar in vivo delivery challenges and clinical development profile to GenEditBio.

TypeDirect peer
Description

Clinical-stage CRISPR gene editing company with allogeneic CAR-T and other cell therapy programs. Comparable gene editing platform development with similar clinical-stage status and strategic focus on genetic disease treatment.

TypeDirect peer
Description

Clinical-stage biotechnology company developing prime editing therapies for genetic diseases. Direct peer in next-generation gene editing platform development with similar clinical-stage profile and therapeutic focus.

TypeEmerging player
Description

LNP delivery technology company supporting multiple gene therapy developers including COVID-19 vaccines. Comparable LNP delivery platform expertise, though operates primarily as enabling technology provider rather than therapy developer.

TypeDirect peer
Description

Clinical-stage CRISPR gene editing company developing in vivo and ex vivo therapies for serious diseases, including ocular programs. Direct competitor to GenEditBio in CRISPR-based genome editing medicines targeting similar indications.

TypeDirect peer
Description

In vivo gene editing company focused on cardiovascular disease, with clinical-stage programs using LNP delivery of base editors. Highly comparable to GenEditBio's GEB-200 program in cardiovascular indications and LNP delivery approach.

TypeDirect peer
Description

Leading in vivo CRISPR/Cas9 gene editing company with clinical-stage programs across multiple therapeutic areas including cardiovascular and rare diseases. Closely comparable technology platform and business model to GenEditBio.

TypeEmerging player
Description

Emerging CRISPR-based gene editing company developing engineered Cas nucleases for therapeutic applications. Emerging player with comparable novel nuclease discovery focus similar to GenEditBio's GenomePAM platform.

TypeDirect peer
Description

CRISPR-Cas9 platform company and GenEditBio's strategic partner through cross-license agreement. Develops genome editing therapeutics with comparable technology stack, though primarily focused on research tools and platform licensing.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

GenEditBio

Gene Therapygeneditbio.com

GenEditBio is a clinical-stage Hong Kong-headquartered biotechnology company developing CRISPR-based in vivo genome-editing therapies for ocular, cardiovascular, and rare genetic diseases, leveraging proprietary LNP and PDV delivery platforms and the AI-integrated GenomePAM nuclease discovery platform.

What GenEditBio does

GenEditBio (GenEditBio Limited) is a clinical-stage biotechnology company founded in 2021 and headquartered in Hong Kong, with research operations in Beijing and a supporting office in Boston. The company develops CRISPR-based in vivo genome-editing therapies — framed as "DNA surgery" — for genetic diseases with unmet medical needs, with primary focus on ocular, metabolic, rare, and cardiovascular indications. Its lead program GEB-101 is a first-in-class, single intrastromal injection CRISPR-Cas therapy for TGFBI corneal dystrophy; it received FDA IND clearance in January 2026 and NMPA clinical trial approval in July 2026, with a Phase 1/2 CLARITY trial underway in the United States. A second program, GEB-200, targets cardiovascular disease and is being advanced through a cross-license with ToolGen.

The company's underlying technology platform integrates three pillars: (1) GenomePAM, an AI-integrated system for PAM characterization and engineering of CRISPR-Cas nucleases using mammalian genome repeats and AlphaFold 3, published in Nature Biomedical Engineering; (2) Protein Delivery Vehicles (PDV), replication-incompetent viral-like particles for in vivo RNP delivery with programmable tissue targeting; and (3) Lipid Nanoparticle (LNP) delivery technology with proprietary NHP-barcoded high-throughput screening. Novel high-fidelity Cas nucleases (SpCas9-HF, SaCas9-HF) and off-target monitoring methods (GUIDE-Seq, EDITED-Seq) underpin the editing precision layer.

GenEditBio is pre-commercial and does not yet generate product revenue. Its forward revenue mechanics are structured around two streams: future therapeutic development and commercialization of its pipeline (potentially via licensing or direct sales through clinical trial sites and ultimately healthcare providers), and technology licensing and partnerships generating upfronts, milestones, and royalties — exemplified by the ToolGen cross-license and the Yimingbio/Ubrigene LNP ex vivo licensing deal. The company sells through enterprise field sales motions targeting pharmaceutical partners, CROs, and global investigators, and reaches investors and partners through international biotech conferences such as the BioCentury-BayHelix East-West Summit and Web Summit Qatar. Backed by $90 million in disclosed financing (April 2024) led by Center Ventures and Shuntian Pharmaceuticals, plus Qiming Venture Partners, HKSTP, and others, and recognized on the Forbes Asia 100 To Watch 2025 list, GenEditBio operates with 51–100 employees across Hong Kong, Beijing, and Boston.

GenEditBio firmographics

Firmographics
Name
GenEditBio
Legal name
GenEditBio Limited
Website
https://geneditbio.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
GenEditBio is a clinical-stage Hong Kong-headquartered biotechnology company developing CRISPR-based in vivo genome-editing therapies for ocular, cardiovascular, and rare genetic diseases, leveraging proprietary LNP and PDV delivery platforms and the AI-integrated GenomePAM nuclease discovery platform.
Ownership category
akta.pro rank

GenEditBio industry classification

Industry
Product category
Gene Therapy
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAACAD
Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAI
Cardiometabolic & Other Systemic Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAL
Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAAIAG
CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Gene editing therapy
  • CRISPR therapeutics
  • Lipid nanoparticle delivery
  • Protein delivery vehicle
  • Genomic medicine

Where GenEditBio is headquartered

Location

Headquarters

HQ city
Hong Kong
HQ country
Hong Kong SAR China
HQ region
Asia

Offices3 records

Markets served

GenEditBio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Therapeutic Development and Commercialization: GenEditBio is a clinical-stage biotechnology company developing CRISPR-based genome editing therapies. The company generates revenue through the development and potential commercialization of its therapeutic pipeline, including GEB-101 for TGFBI corneal dystrophy and GEB-200 for cardiovascular disease.
  2. Technology Licensing and Partnerships: The company engages in strategic licensing agreements and partnerships, such as the cross-license agreement with ToolGen, to develop and commercialize genome-editing therapeutics, generating revenue through upfront payments, milestone payments, and royalties.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

GenEditBio product offering

Product offering

Core offering

GenEditBio is a clinical-stage biotechnology company developing CRISPR-Cas based in vivo genome editing therapies for genetic diseases. Its integrated platform combines proprietary lipid nanoparticle (LNP) and protein delivery vehicle (PDV) delivery technologies, novel Cas nucleases, and the GenomePAM AI platform for nuclease discovery. The lead clinical asset GEB-101 is a first-in-class CRISPR therapy for TGFBI corneal dystrophy, with GEB-200 in development for cardiovascular disease.

Product overview

GenEditBio is a clinical-stage biotechnology company developing CRISPR-based precision genome editing medicines. The company's integrated platform combines three core technologies: LNP (Lipid Nanoparticle) delivery technology for organ/tissue targeting, PDV (Protein Delivery Vehicle) for viral-like in vivo RNP delivery, and GenomePAM for AI-powered CRISPR-Cas nuclease discovery and engineering. The lead clinical program GEB-101 is a first-in-class CRISPR therapy for TGFBI corneal dystrophy, with GEB-200 in development for cardiovascular disease. The company focuses on 'one-and-done' in vivo gene editing therapies targeting ocular, metabolic, and rare diseases.

Differentiator

Problem solved

Functional benefit

Products and services

  • GEB-101 First-in-class CRISPR-Cas based in vivo genome editing therapy for TGFBI corneal dystrophy, delivered via single intrastromal injection using ribonucleoprotein (RNP) formulation. Targeting patients with TGFBI corneal dystrophy.
  • GEB-200 In vivo genome editing therapeutic candidate for cardiovascular disease, developed in collaboration with ToolGen using CRISPR-Cas9 platform and GenEditBio's lipid nanoparticle delivery technology. Targets cardiovascular genetic conditions with unmet needs.
  • GenomePAM Platform AI-integrated scalable platform for protospacer adjacent motif (PAM) characterization and engineering of CRISPR-Cas nucleases using mammalian genome repeats. Achieves at least 10-bit width PAM analysis compared to traditional 5-6 bit width methods, accelerating novel Cas nuclease discovery.
  • Protein Delivery Vehicle (PDV) Proprietary replication-incompetent viral-like particle for in vivo delivery of genome editors as RNP, featuring programmable tissue targeting via surface glycoproteins and molecules, high cargo compatibility and large cargo capacity.
  • Lipid Nanoparticle (LNP) Delivery Technology Proprietary lipid nanoparticle delivery platform featuring barcoding technology that enables high-throughput screening directly on nonhuman primates, with diverse lipid components enabling organ/tissue targeting without requiring antibody conjugation.

Quantifiable outcome

  • FDA IND clearance achieved for GEB-101, marking transition from preclinical to clinical stage
  • +2 more outcomes

Companies that use GenEditBio

Customer profile

Segments1 record

Ideal customer profiles3 records

GenEditBio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

GenEditBio partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • 宜明生物 (Yimingbio/Ubrigene)coreStrategic or Co-development Partner · 26 January 2026Strategic collaboration to develop next-generation LNP ex vivo delivery technology. Yimingbio licensed GenEditBio's LNP technology for ex vivo applications and will leverage its global CRDMO production services for engineering integration and product development. Focus on developing efficient, low-toxicity RNA-LNP ex vivo delivery standardized ready-to-use reagent products for cell and gene therapy.
  • ToolGen Inc.coreTechnology or Integration · 24 November 2025Strategic cross-license agreement for the development of in vivo genome-editing therapeutics. Collaboration leverages ToolGen's CRISPR-Cas9 platform and GenEditBio's lipid nanoparticle delivery technology. Focuses on 'once-and-done' treatment for diseases with unmet needs, with promising preclinical results on GEB-200 for cardiovascular disease.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

GenEditBio competitors and assessment

Company assessment

Direct peers

  • CRISPR Therapeutics: Pioneering CRISPR/Cas9-based gene editing company with approved therapy (Casgevy) and broad pipeline. Direct peer with overlapping gene editing platform and delivery technology approaches for in vivo applications.
  • Beam Therapeutics: Clinical-stage precision genetic medicines company developing base editing therapies for serious diseases. Comparable gene editing platform with similar in vivo delivery challenges and clinical development profile to GenEditBio.
  • Caribou Biosciences: Clinical-stage CRISPR gene editing company with allogeneic CAR-T and other cell therapy programs. Comparable gene editing platform development with similar clinical-stage status and strategic focus on genetic disease treatment.
  • Prime Medicine: Clinical-stage biotechnology company developing prime editing therapies for genetic diseases. Direct peer in next-generation gene editing platform development with similar clinical-stage profile and therapeutic focus.
  • Editas Medicine: Clinical-stage CRISPR gene editing company developing in vivo and ex vivo therapies for serious diseases, including ocular programs. Direct competitor to GenEditBio in CRISPR-based genome editing medicines targeting similar indications.
  • Verve Therapeutics: In vivo gene editing company focused on cardiovascular disease, with clinical-stage programs using LNP delivery of base editors. Highly comparable to GenEditBio's GEB-200 program in cardiovascular indications and LNP delivery approach.
  • Intellia Therapeutics: Leading in vivo CRISPR/Cas9 gene editing company with clinical-stage programs across multiple therapeutic areas including cardiovascular and rare diseases. Closely comparable technology platform and business model to GenEditBio.
  • ToolGen Inc. CRISPR-Cas9 platform company and GenEditBio's strategic partner through cross-license agreement. Develops genome editing therapeutics with comparable technology stack, though primarily focused on research tools and platform licensing.

Emerging players

  • Acuitas Therapeutics: LNP delivery technology company supporting multiple gene therapy developers including COVID-19 vaccines. Comparable LNP delivery platform expertise, though operates primarily as enabling technology provider rather than therapy developer.
  • Scribe Therapeutics: Emerging CRISPR-based gene editing company developing engineered Cas nucleases for therapeutic applications. Emerging player with comparable novel nuclease discovery focus similar to GenEditBio's GenomePAM platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

GenEditBio social profiles

Digital presence

GenEditBio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

GenEditBio leadership team

Management profile

Number of profiles

Profiles2 records

GenEditBio funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

GenEditBio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GenEditBio

What does GenEditBio do?

GenEditBio is a clinical-stage biotechnology company developing CRISPR-Cas based in vivo genome editing therapies for genetic diseases. Its integrated platform combines proprietary lipid nanoparticle (LNP) and protein delivery vehicle (PDV) delivery technologies, novel Cas nucleases, and the GenomePAM AI platform for nuclease discovery. The lead clinical asset GEB-101 is a first-in-class CRISPR therapy for TGFBI corneal dystrophy, with GEB-200 in development for cardiovascular disease.

Is GenEditBio a public or private company?

GenEditBio is a private company. It is classified as venture growth investor backed and is currently operating.

When was GenEditBio founded?

GenEditBio was founded in 2021. It employs 11 to 50 people.

Where is GenEditBio based?

GenEditBio is headquartered in Hong Kong, Hong Kong SAR China, in the Asia region.

How does GenEditBio make money?

Two revenue lines are on record. Therapeutic Development and Commercialization is the primary driver. The others are technology Licensing and Partnerships.

Who are GenEditBio's main competitors?

Direct peers on record are CRISPR Therapeutics, Beam Therapeutics, Caribou Biosciences, Prime Medicine, Editas Medicine, Verve Therapeutics, Intellia Therapeutics and ToolGen Inc.. Emerging players are Acuitas Therapeutics and Scribe Therapeutics.

Does GenEditBio have an API?

No public API is recorded for GenEditBio.

What industry is GenEditBio in?

GenEditBio's product category is Gene Therapy. Its primary akta.pro industry code is HLAAACAD, Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo), with a secondary code of HLAAACAE, Gene Therapy for Rare/Monogenic Diseases. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
South China Morning PostHow could a single gene-editing injection treat inherited eye diseases?GenEditBio is testing a one-shot gene-editing therapy for TGFBI-related corneal dystrophies, inherited eye conditions that can progressively damage sight. The therapy aims to treat these diseases at their genetic source. Professor Zheng Zongli, who co-founded the company, has spent 15 years developing safe gene-editing therapies.Media-outreachHKSTP Park Company Wins 2nd Runner-Up in Rocket Fuel East Startup CompetitionMEINUNG ROBOT, a company in the HKSTP ecosystem, won 2nd Runner-Up in the Rocket Fuel East Startup Competition at LEAP East 2026, securing a US$10,000 equity-free award among over 500 competing startups, while GenEditBio also advanced to the Top 6 finalists. HKSTP served as the exclusive Tech Ecosystem Partner at LEAP East 2026 in Hong Kong, bringing together over 30 park companies to facilitate more than 1,500 business discussions and meetings from July 8–10. The pavilion showcased innovations from 23 companies across Life and Health Tech, GreenTech, Smart Cities, and AI sectors, attracting over 3,000 visits.Hong Kong BusinessHong Kong healthcare pushes pricing clarity, trials, and biotech capacityHong Kong's healthcare sector is shifting to pricing transparency and clinical trial capacity amid rising costs. Six in 10 patients delay treatment due to cost uncertainty, and medical cost inflation is forecast to reach 9.9% in 2026. The government plans to expand trial capacity and improve drug approval pathways.The StandardHKSTP leads five high-potential biotech startups to explore global collaboration and financing at premier biopharma summit in SeoulHKSTP led a delegation of five high-potential biotech startups from Hong Kong to the 5th BioCentury-BayHelix East-West Summit in Seoul, South Korea, to explore global collaboration and financing opportunities. The startups—AilsynBio, GenEditBio, Immuno Cure, OBpharm, and SPH Biotherapeutics—presented solutions in AI drug development and immunotherapy, securing cooperation intent on co-development and technology licensing with Korean and international pharmaceutical companies. The summit also highlighted Hong Kong's strengths in talent density, clinical trial capabilities, and legal infrastructure for cross-border transactions as key advantages for attracting international biotech investment.TechCrunchHow AI is helping solve the labor issue in treating rare diseasesExecutives from Insilico Medicine and GenEditBio discussed at Web Summit Qatar how AI is being leveraged to address labor shortages in rare disease drug discovery, with Insilico launching its 'MMAI Gym' platform to train generalist AI models for multi-task pharmaceutical applications. GenEditBio announced FDA approval to begin clinical trials of its CRISPR therapy for corneal dystrophy, using AI-designed delivery vehicles to enable in vivo gene editing. Both companies argue AI-driven automation can dramatically reduce costs and time in drug development while making treatments more accessible globally.TechbuzzAI tackles rare disease labor gap with gene editing automationExecutives from Insilico Medicine and GenEditBio presented AI-driven drug discovery and gene editing platforms at Web Summit Qatar, addressing a labor shortage that has left thousands of rare diseases without treatment options. Insilico Medicine unveiled its MMAI Gym platform to train generalist AI models for scalable drug discovery, while GenEditBio received FDA approval for in vivo CRISPR trials targeting corneal dystrophy. Both companies aim to reduce the cost and complexity of personalized therapies, with GenEditBio's approach using AI-designed delivery vehicles to enable off-the-shelf gene editing treatments.PR NewswireGenEditBio Receives FDA Clearance of IND Application for Its Lead In Vivo Genome-Editing Program GEB-101 for TGFBI Corneal DystrophyGenEditBio Limited announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application to initiate Phase 1/2 CLARITY trial activities for GEB-101, its lead in vivo genome-editing program targeting TGFBI corneal dystrophy. The trial will evaluate safety, tolerability, and efficacy of GEB-101, a first-in-class CRISPR-Cas based therapy delivered via a single intrastromal injection, with patient enrollment expected to begin in the second quarter. The company plans to expand the trial through regulatory clearance in other major markets following the U.S. study.PR NewswireToolGen and GenEditBio Enter Strategic Cross-License Agreement to Accelerate Development of Innovative Genome-Editing TherapeuticsToolGen Inc., a Korean genome editing company listed on KOSDAQ, and GenEditBio Limited, a Hong Kong-headquartered clinical-stage biotechnology company, have entered into a strategic cross-license agreement combining ToolGen's CRISPR-Cas9 genome editing platform with GenEditBio's lipid nanoparticle (LNP) delivery technology for developing in vivo genome-editing therapeutics. The two companies announced they recently completed a successful proof-of-concept study in non-human primates for their lead program GEB-200, an investigational therapy targeting lipoprotein(a) to treat atherosclerotic cardiovascular disease, representing a key milestone toward IND submission. The companies plan to accelerate the regulatory path for GEB-200 and jointly explore global licensing opportunities under the agreement.South China Morning PostHong Kong life and health tech entrepreneurs on shared quest to make the world healthierThree Hong Kong life and health tech entrepreneurs discussed their global healthcare visions during a breathwork session. Their companies include Immuno Cure, GenEditBio, and Applied Technology, with products in clinical trials and platforms used by over 10,000 doctors. They see Hong Kong as a key hub for future healthcare innovation.